| INTRODUCTION
Androgens and androgen receptor (AR) play essential roles in the development and progression of prostate cancer. [1] [2] [3] [4] [5] [6] [7] Androgen deprivation therapy (ADT) has been the mainstay of treatment for men with advanced hormone-sensitive prostate cancer. Unfortunately, prostate cancer eventually becomes resistant to ADT and progresses to castration-resistant prostate cancer (CRPC). While CRPC is usually fatal, [8] [9] [10] [11] [12] the survival of patients with CRPC can be highly variable. 13 Existing nomograms and prognostic tools do not account for the great biologic and clinical heterogeneity of CRPC and improvement in prognostication is needed to optimize patient stratification and treatment. [13] [14] [15] [16] [17] [18] [19] We previously tested the hypothesis that expression of genes in whole blood derived cells could yield prognostic information in men with CRPC. We developed a whole blood RNA transcript-based prognostic model in CRPC, which predicted the overall survival (OS) of men with CRPC. 24 Of 168 inflammation and prostate cancer-related genes tested, decreased expression of ABL2, SEMA4D, and ITGAL and increased expression of C1QA, TIMP1, and CDKN1A was significantly associated with prolonged OS in two independent cohorts. The sixgene model was able to distinguish two prognostic groups that had a 2.2 years difference in OS. ABL2, ITGAL, and SEMA4D are involved in Tcell motility, antigen surveillance, and T-helper cell activity. [25] [26] [27] [28] [29] The downregulation of these genes indicates a downregulation of cellular and humoral immunity. C1QA, CDKN1A, and TIMP1 showed increased expression in enriched monocytes, presumably indicating a process driving monocyte differentiation toward the production of tissue macrophages and away from dendritic cells. [30] [31] [32] [33] [34] [35] Taken together, these observations suggested that alterations of the immune system toward macrophage differentiation, with a decrease in cellular and humoral immunity, might have a significant impact on OS. To further explore this finding, we studied the association of inherited variation in these six genes on prognosis in two independent CRPC cohorts. We hypothesized that genetic variation might modify their biologic effect and in turn the association with OS. Table S1 ) including all four SNPs selected for TIMP1.
| PATIENTS AND METHODS

| Patient population
Thus, the final analysis contained 59 SNPs from five genes: 15 in ABL2, 3 in C1QA, 4 in CDKN1A, 15 in ITGA, and 22 in SEMA4D. Genomic DNA was prepared from whole blood using a QIAamp DNA Blood mini kit (Qiagen Inc, Valencia, CA). Genotyping was done using Sequenom iPLEX matrix-assisted laser desorption/ionization-time of flight mass spectrometry technology at the core facility of Boston Children Hospital.
| Statistical methods
The primary outcome was OS, defined as the period from diagnosis of CRPC to patient death from any cause, with censoring on the day of last follow-up. The distribution of OS according to genotypes was estimated using the Kaplan-Meier method. Log-rank tests were performed to test the association between individual SNPs and OS.
In the test cohort, each SNP was treated as a categorical variable with a common homozygote, a rare homozygote, and a heterozygote allele. Rare homozygotes were combined withheterozygotes if the proportion of rare homozygotes was below 0.02. We also combined homozygotes and heterozygotes if they showed a similar association with the outcome (OS), which significantly differed from the other homozygous genotype (for two SNPs). As we were testing 59 different SNPs, false discovery rates (FDR) were reported to account for multiple comparisons. 37 For a subset of SNPs selected on the basis of log-rank test results (P < 0.05), we performed multivariable Cox regression models adjusted for known clinical prognostic factors including biopsy Gleason score, time to progression on primary ADT, metastatic status, PSA and age at diagnosis of CRPC. The top SNPs (P < 0.05) were selected for further validation if there was statistical significant association in the multivariable models. Similar analyses were conducted in the validation cohort to confirm findings for the selected SNPs.
To validate that the SNPs functioned as expression Quantitative
Trait Loci (eQTL), we used the Genotype-Tissue Expression (GTEx)
resource. The data used for the analyses described in this manuscript, including beta distribution-adjusted empirical P-values from FastQTL, were obtained from https://www.gtexportal.org/ on 05/30/2018.
Statistical analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC). All P values are two sided.
3 | RESULTS
| Patient characteristics
The demographic, disease, and past treatment characteristics of the test cohort (N = 600) and validation cohort (N = 223) are presented in 
| Association of genetic variations with OS in the CRPC test cohort
In total, 59 SNPs covering five gene loci (ABL2, C1QA, CDKN1A, ITGAL, and SEMA4D) were analyzed in the test cohort (Supplemental Table S2 ). Two SNPs in ABL2 (rs1318056 and rs1490311) and two in ITGAL (rs2073917 and rs3764322) were associated with OS, with unadjusted P-values <0.05 and FDR<0.35 (Table 2 , Figure 1 , Supplemental Table S2 ). The linkage between ITGAL-rs2073917 and ITGAL-rs3764322 loci was low (r 2 = 0.01). The detailed genotype distributions of the four SNPs are summarized in Supplemental Table S3 . 
| Association of genetic variations with OS in the validation cohort
Four polymorphisms in ABL2 (rs1318056 and rs1490311) and in ITGAL (rs2073917 and rs3764322) were genotyped in an independent validation cohort. We observed a similar trend and impact on OS in the validation cohort for ABL2-rs1318056 (aHR, Table 2 .
| Association of genetic variations with gene expression in GTEx
Since the six-gene prognostic model for CRPC was originally identified based on the transcriptional profiling of whole blood, we validated the association of the four positive SNPs with mRNA expression in blood and prostate tissue. In this eQTL analysis, we observed that the minor alleles of the two SNPs in ABL2 (rs1318056, rs1490311) were associated decreased ABL2 mRNA expression in whole blood (rs1318056, P = 0.035; rs1490311, P = 0.015; Figure 2 ). The two SNPs in ITGAL were not associated with ITGAL mRNA levels (rs2073917, P = 0.86; rs3764322, P = 0.9). Neither of the SNPs in ABL2 or ITGAL was associated with mRNA expression in normal prostate tissue (all P > 0.44).
| DISCUSSION
We previously identified a whole blood RNA transcript-based model consisting of a six-gene signature of immune function or inflammatory response genes, which was prognostic for OS in cohorts of men with CRPC. In the current work, we tested the association of SNPs from the six genes with survival in a test and a validation cohort of patients with CRPC. The major homozygote of ABL2-rs1318056 and the minor homozygote of ITGAL-rs2073917 were significantly associated with (12) 121 ( Unfortunately, all SNPs in TIMP1 failed genotyping and thus we were unable to examine these effects. Further eQTL analysis indicated that the minor alleles of rs1318056 and rs1490311, which are associated longer OS, were associated with decreased ABL2 mRNA expression in whole blood. This result corroborated our initial finding that decreased expression of ABL2 is associated lower risk of CRPC and better OS. 24 Several studies have shown that gene expression profiles in peripheral blood cells can help to distinguish controls from patients with various diseases. [20] [21] [22] [23] There is some evidence that white blood cell signatures can also be used for prognostication. The peripheral A limitation of this study includes the small size of validation cohort, which may have led to some findings not replicating. In addition, our prognostic models did not include some that have been shown to be prognostic in CRPC, such as lactate dehydrogenase (LDH), hemoglobin, and alkaline phosphatase (ALP). Given that we tested 59 SNPs, we reported of false discovery rates to account for multiple testing, 37 and we leveraged an independent validation cohort. We note that the two SNPs in ITGAL were not associated with ITGAL mRNA expression. However, this testing in the GTEx resource may have lacked power and was performed in blood from individuals without CRPC. Furthermore, this was a hypothesisgenerating study following our initial work on RNA expression of genes involved in immune function and inflammatory response. In conclusion, we identified polymorphisms in genes that are involved in the immune system and macrophage differentiation may be associated with the OS in men with CRPC. Further studies are needed to validate these findings and to explore functionality.
ACKNOWLEDGMENTS
The study was supported in part by funding from the Dana-Farber 
